Log in

Oncolytics Biotech Stock Price, Forecast & Analysis (NASDAQ:ONCY)

$1.10
+0.09 (+8.91 %)
(As of 11/22/2019 05:32 AM ET)
Today's Range
$1.03
Now: $1.10
$1.13
50-Day Range
$0.36
MA: $0.75
$1.38
52-Week Range
$0.35
Now: $1.10
$2.69
Volume916,600 shs
Average Volume215,584 shs
Market Capitalization$27.51 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCY
CUSIPN/A
CIKN/A
Phone403-670-7377

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.27 per share

Profitability

Net Income$-13,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$27.51 million
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable

Receive ONCY News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.


Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (NASDAQ:ONCY) announced its earnings results on Friday, August, 3rd. The company reported ($0.21) EPS for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.25. View Oncolytics Biotech's Earnings History.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Oncolytics Biotech.

What price target have analysts set for ONCY?

1 brokerages have issued 12-month price targets for Oncolytics Biotech's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Oncolytics Biotech's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 536.4% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.

What is the consensus analysts' recommendation for Oncolytics Biotech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.

Has Oncolytics Biotech been receiving favorable news coverage?

Headlines about ONCY stock have been trending negative on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oncolytics Biotech earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Oncolytics Biotech.

Are investors shorting Oncolytics Biotech?

Oncolytics Biotech saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 527,600 shares, an increase of 351.3% from the September 30th total of 116,900 shares. Based on an average trading volume of 482,600 shares, the days-to-cover ratio is presently 1.1 days. Approximately 2.2% of the shares of the stock are short sold. View Oncolytics Biotech's Current Options Chain.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Rita Laeufle, Chief Medical Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)

How do I buy shares of Oncolytics Biotech?

Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $1.10.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of $27.51 million. The company earns $-13,140,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. View Additional Information About Oncolytics Biotech.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]


MarketBeat Community Rating for Oncolytics Biotech (NASDAQ ONCY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: What is the Quick Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel